Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

141. Smoking, Not COPD, as the Disease. (PubMed)

Smoking, Not COPD, as the Disease. Smoking, Not COPD, as the Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27168438 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard (...) Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 12;374(19):1885-6. doi: 10.1056/NEJMe1515508. Smoking, Not COPD, as the Disease. 1 . 1 From Dipartimento di Medicina Metabolica, Nuovo Ospedale Civile Sant'Agostino Estense, Azienda Unitá Sanitaria Locale di Modena, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, Modena, Italy. Comment on [N Engl

2016 NEJM

142. Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms (PubMed)

Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms 27730188 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms. 00032-2016 Battle against COPD: time to reinforce the primary healthcare units of rural areas of India to combat lung diseases http://ow.ly/ZAwge. Kalkana Toshita T Dept of Pneumology, Allergy and Asthma Research Centre

Full Text available with Trip Pro

2016 ERJ open research

143. Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects (PubMed)

Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects 27730194 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects. 00094-2015 The forced oscillation technique (FOT) is gaining clinical acceptance, facilitated by more commercial devices and clinical data (...) . However, the effects of variations in testing protocols used in FOT data acquisition are unknown. We describe the effect of duration of data acquisition on FOT results in subjects with asthma, chronic obstructive pulmonary disease (COPD) and healthy controls. FOT data were acquired from 20 healthy, 22 asthmatic and 18 COPD subjects for 60 s in triplicate. The first 16, 30 and 60 s of each measurement were analysed to obtain total, inspiratory and expiratory resistance of respiratory system ( R rs

Full Text available with Trip Pro

2016 ERJ open research

144. Home health monitoring compared with usual care for patients with moderate to severe COPD

Home health monitoring compared with usual care for patients with moderate to severe COPD evidence note In response to an enquiry from Quality and Efficiency Support Team, Scottish Government Number 60 March 2016 What is the clinical effectiveness, cost effectiveness and safety of home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease? What is an evidence note Evidence notes are rapid reviews of published secondary clinical (...) recommendations for NHSScotland, however the Scottish Health Technologies Group (SHTG) produce an Advice Statement to accompany all evidence reviews. Definitions Chronic obstructive pulmonary disease: is a lung disease characterised by chronic airflow obstruction that is not fully reversible and usually progressive 1 . Exacerbation: characterised by the rapid and sustained worsening of respiratory symptoms beyond normal daily variations 1 . Bronchitis: inflammation that narrows the bronchi (the tubes carrying

2016 Evidence Notes from Healthcare Improvement Scotland

145. Economic surveillance for chronic obstructive pulmonary disease (COPD) in Alberta

Economic surveillance for chronic obstructive pulmonary disease (COPD) in Alberta Economic Report Economic surveillance for chronic obstructive pulmonary disease (COPD) in Alberta REVISED, August 2016 INSTITUTE OF HEALTH ECONOMICS The Institute of Health Economics (IHE) is an independent, not-for-profit organization that performs research in health economics and synthesizes evidence in health technology assessment to assist health policy making and best medical practices. IHE BOARD OF DIRECTORS (...) Access, AstraZeneca Ms. Jennifer Chan – VP, Policy & Communications, Merck Canada Ms. Tanya Lederer – Director, External Relations, GlaxoSmithKline Inc. IHE Mr. Doug Gilpin – Chair, Audit & Finance Committee Dr. Egon Jonsson – Executive Director & CEO, Institute of Health Economics Ms. Allison Hagen – Director of Finance, Operations & Administration, Institute of Health Economics Economic Report Economic surveillance for chronic obstructive pulmonary disease (COPD) in Alberta Contributing authors

2016 Institute of Health Economics

146. Home health monitoring compared with usual care for patients with moderate to severe COPD

Home health monitoring compared with usual care for patients with moderate to severe COPD File name: 2016-003 AS COPD v1.0.doc Version: 1.0 Date: 21 March 2016 Produced by: SHTG Page: 1 Review date: March 2018 Advice Statement 003/2016 March 2016 What is the clinical effectiveness, cost effectiveness, safety and patient satisfaction of home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease? This advice has been produced (...) following completion of evidence note 60 by Healthcare Improvement Scotland, in response to an enquiry from the Quality and Efficiency Support Team Background In 2012/2013, practice team information data estimated that about 20 women and 18 men per 1,000 patients, across all ages, consulted a general practitioner or practice nurse at least once due to chronic obstructive pulmonary disease (COPD). The Scottish Government’s national telehealth and telecare delivery plan includes an objective to expand

2016 SHTG Advice Statements

147. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation (PubMed)

Physical activity assessed in routine care predicts mortality after a COPD hospitalisation 27730174 2018 11 13 2312-0541 2 1 2016 Jan ERJ open research ERJ Open Res Physical activity assessed in routine care predicts mortality after a COPD hospitalisation. 00062-2015 The independent relationship between physical inactivity and risk of death after an index chronic obstructive pulmonary disease (COPD) hospitalisation is unknown. We conducted a retrospective cohort study in a large integrated (...) healthcare system. Patients were included if they were hospitalised for COPD between January 1, 2011 and December 31, 2011. All-cause mortality in the 12 months after discharge was the primary outcome. Physical activity, expressed as self-reported minutes of moderate to vigorous physical activity (MVPA), was routinely assessed at outpatient visits prior to hospitalisation. 1727 (73%) patients were inactive (0 min of MVPA per week), 412 (17%) were insufficiently active (1-149 min of MVPA per week) and 231

Full Text available with Trip Pro

2016 ERJ open research

148. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit (PubMed)

Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit 27730166 2018 11 13 2312-0541 2 1 2016 Jan ERJ open research ERJ Open Res Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. 00034-2015 Chronic obstructive pulmonary disease (COPD) care across Europe has high heterogeneity with respect to cost and the services available. Variations in length of stay (LOS) may be attributed to patient characteristics, resource (...) and organisational characteristics, and/or the so-called hospital cluster effect. The European COPD Audit in 13 countries included data from 16 018 hospitalised patients. The recorded variables included information on patient and disease characteristics, and resources available. Variables associated with LOS were evaluated by a multivariate, multilevel analysis. Mean±sd LOS was 8.7±8.3 days (median 7 days, interquartile range 4-11 days). Crude variability between countries was reduced after accounting

Full Text available with Trip Pro

2016 ERJ open research

149. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD Global Strategy for Diagnosis, Management, and Prevention of COPD - 2016 - Global Initiative for Chronic Obstructive Lung Disease - GOLD Global Strategy for Diagnosis, Management, and Prevention of COPD – 2016 Please reference this document as follows: From the Global Strategy for the Diagnosis, Management and Prevention of COPD , Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Available from: http (...) ://goldcopd.org/. GOLD documents are protected by copyright. A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. Click here to by the GOLD Science Committee to prepare the 201 updates of the documents. In 2011, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD. It

2016 European Respiratory Society

150. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD (PubMed)

Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD 26769015 2016 01 15 2016 05 17 2016 11 26 1468-3296 71 2 2016 Feb Thorax Thorax Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. 133-40 10.1136/thoraxjnl-2015-207775 Hospitalisation due to acute exacerbations of COPD (AECOPD) is common, and subsequent mortality high. The DECAF score was derived for accurate prediction of mortality and risk stratification (...) Kingdom epidemiology PMC4752621 COPD Exacerbations 2016 1 16 6 0 2016 1 16 6 0 2016 5 18 6 0 ppublish 26769015 thoraxjnl-2015-207775 10.1136/thoraxjnl-2015-207775 PMC4752621

Full Text available with Trip Pro

2016 EvidenceUpdates

151. Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients

Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients Article Text Therapeutics/Prevention Randomised controlled trial LABA/LAMA combinations instead of LABA/ICS combinations may

2016 Evidence-Based Medicine (Requires free registration)

152. Cohort study: A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women

Cohort study: A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women Article Text Aetiology/Harm Cohort study A higher overall diet quality is inversely associated

2016 Evidence-Based Medicine (Requires free registration)

153. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD Global Strategy for Diagnosis, Management, and Prevention of COPD - 2016 - Global Initiative for Chronic Obstructive Lung Disease - GOLD Global Strategy for Diagnosis, Management, and Prevention of COPD – 2016 Please reference this document as follows: From the Global Strategy for the Diagnosis, Management and Prevention of COPD , Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Available from: http (...) ://goldcopd.org/. GOLD documents are protected by copyright. A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. Click here to by the GOLD Science Committee to prepare the 201 updates of the documents. In 2011, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD. It

2016 European Respiratory Society

154. Co-morbidities in 99 COPD patients: A case series from Syria (PubMed)

Co-morbidities in 99 COPD patients: A case series from Syria 27847908 2018 11 13 2450-131X 3 4 2015 Oct-Dec Journal of translational internal medicine J Transl Int Med Co-morbidities in 99 COPD patients: A case series from Syria. 167-170 To assess the most frequent co-morbidities in chronic obstructive pulmonary disease (COPD) patients. We studied 99 patients, including 72 males and 67 smokers, presented to our University Hospital in Lattakia, Syria in 2012, with a mean age of 63 years. Overall (...) , there were 61% hypertension, 37% ischemic heart disease, 25% diabetes, 45% anemia, and 47% pulmonary hypertension. Other diseases were less significant. Patients who had more severe Global Initiative for Chronic Obstructive Lung Disease stage had a greater number of co-morbidities. We recommend as a general practice, to assess cardiac co-morbidities, hypertension, and other co-morbidities in all COPD patients and vice versa. We also recommend performing spirometry in smokers complaining of chronic cough

Full Text available with Trip Pro

2015 Journal of translational internal medicine

155. In patients with COPD, do self-management action plans improve outcomes over usual care?

In patients with COPD, do self-management action plans improve outcomes over usual care? In patients with COPD, do self-management action plans improve outcomes over usual care? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics In patients with COPD, do self-management action plans improve outcomes over usual care? View (...) / Open Date 2015-08 Format Metadata Abstract In patients with COPD, do self-management action plans improve outcomes over usual care? Evidence-Based Answer: In patients with moderate to severe chronic obstructive pulmonary disease (COPD), isolated action plans do not decrease healthcare utilization or improve health related quality of life and have variable effects on use of oral corticosteroids and antibiotics (SOR: A, systematic review of RCTs). Action plans may slightly shorten time to symptom

2015 Evidence Based Practice

156. Without spirometry, how accurate is the diagnosis of COPD?

Without spirometry, how accurate is the diagnosis of COPD? Without spirometry, how accurate is the diagnosis of COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Without spirometry, how accurate is the diagnosis of COPD? View/ Open Date 2015-09 Format Metadata Abstract Without spirometry, how accurate (...) is the diagnosis of COPD? Evidence-Based Answer: Smoking history, a previous history of respiratory disease, abnormal breath sounds on examination, and a prolonged expiratory time may help in the diagnosis of chronic obstructive pulmonary disease (COPD); overall clinical impression is 83% sensitive. However, using clinical history and examination alone would still miss many patients with COPD on spirometry (SOR: B, based on systematic review and cross-sectional trials). URI Part of Citation Evidence

2015 Evidence Based Practice

157. Tiotropium/olodaterol (Spiolto Respimat) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Tiotropium/olodaterol (Spiolto Respimat) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Published 09 November 2015 Product Update: tiotropium/olodaterol 2.5 microgram/ 2.5 microgram inhalation solution (Spiolto ® Respimat ® ) SMC No. (1099/15) Boehringer Ingelheim Ltd 9 October 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission tiotropium/olodaterol (Spiolto ® Respimat ® ) is accepted for use within NHS Scotland. Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Spiolto ® Respimat ® should be used in patients for whom tiotropium and olodaterol are appropriate choices of antimuscarinic and long

2015 Scottish Medicines Consortium

158. Smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit

Smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit

2015 European Respiratory Society

159. Glycopyrronium bromide. Seebri, Enurev Breezhaler in COPD. We´re not breathing anything new under the sun

Glycopyrronium bromide. Seebri, Enurev Breezhaler in COPD. We´re not breathing anything new under the sun 2015. DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD Content tools Share it We´re (...) not breathing anything new under the sun Glycopyrronium bromide is an inhaled long-acting muscarinic antagonist (LAMA) approved for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). The only head-to-head trial published to date showed noninferiority vs tiotropium but not superiority. The average change with respect to baseline FEV1 trough was 103 mL (glycopyrronium) vs 99 mL (tiotropium), but there was no clinical relevance (120 mL). Safety profile remains

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

160. An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial (PubMed)

An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial 25811395 2015 07 07 2015 09 21 2017 02 20 1931-3543 148 1 2015 Jul Chest Chest An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial. 128-37 10.1378/chest.14-1466 Low levels of physical activity (PA) are associated with poor outcomes in people (...) with COPD. Interventions to increase PA could improve outcomes. We tested the efficacy of a novel Internet-mediated, pedometer-based exercise intervention. Veterans with COPD (N = 239) were randomized in a 2:1 ratio to the (1) intervention group (Omron HJ-720 ITC pedometer and Internet-mediated program) or (2) wait-list control group (pedometer). The primary outcome was health-related quality of life (HRQL), assessed by the St. George's Respiratory Questionnaire (SGRQ), at 4 months. We examined the SGRQ

Full Text available with Trip Pro

2015 EvidenceUpdates